{
    "nctId": "NCT05599334",
    "briefTitle": "A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib",
    "officialTitle": "A Retrospective Observational Study of Adult Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib as Extended Adjuvant Therapy in the Context of the European Early Access Program (NEAR)",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Adjuvant Therapy, HER2-positive Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 130,
    "primaryOutcomeMeasure": "Description of age",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients will be eligible for inclusion if they fulfill all of the following criteria:\n\n  * Age \u2265 18 years at neratinib treatment initiation\n  * Having received at least one initial dose of neratinib as an extended adjuvant therapy for the treatment of early-stage HER2+ breast cancer, in the context of the EAP in Europe, and between August 01, 2017 and December 31, 2020\n  * Patients (or next of kin/legal representative, if applicable) who provide written informed consent or non-opposition.\n\nExclusion Criteria:\n\n* N/A",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}